🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 7 of 151

  1. ADX10059

    Addex Therapeutics

    Gastroesophageal Reflux

    phase 2 small molecule completed

    2 trials

  2. ADX48621

    Addex Therapeutics

    Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  3. AEF0117

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Abuse

    phase 2 small molecule completed

    1 trial

  4. AEVI-001

    Avalo Therapeutics

    Attention Deficit Hyperactivity Disorder

    phase 2 small molecule completed

    2 trials

  5. AFM13

    Artiva Biotherapeutics

    Relapsed or Refractory Hodgkin Lymphoma

    phase 2 small molecule terminated

    1 trial

  6. AG-013736

    Pfizer

    Thyroid Neoplasms

    phase 2 small molecule completed

    1 trial

  7. AG-120

    Agios Netherlands B.V.

    Chondrosarcoma

    phase 2 small molecule active

    1 trial

  8. AG-120/S95031 250mg film-coated tablet, IMFINZI 50 mg/mL concentrate for solution for infusion., Gemcitabin Hikma 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    The George Institute

    Locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation

    phase 2 small molecule active

    1 trial

  9. AG-348

    Agios Netherlands B.V.

    Thalassemia

    phase 2 small molecule active

    1 trial

  10. AG10

    BridgeBio Oncology Therapeutics

    Amyloid Cardiomyopathy

    phase 2 small molecule active

    1 trial

  11. AG10

    BridgeBio Oncology Therapeutics

    Familial ATTR-CM (ATTRm-CM, or FAC)

    phase 2 small molecule completed

    1 trial

  12. AGMB-129

    Agomab Therapeutics NV

    Fibrostenotic Crohn's Disease

    phase 2 small molecule active

    2 trials

  13. AGN 211745

    Allergan Pharmaceuticals International Limited

    Choroid Neovascularization

    phase 2 small molecule terminated

    1 trial

  14. AIR DNase™

    Protalix BioTherapeutics

    Cystic Fibrosis

    phase 2 small molecule active

    1 trial

  15. AK0529

    Shanghai University of Traditional Chinese Medicine

    RESPIRATORY SYNCYTIAL VIRUS INFECTIONS

    phase 2 small molecule completed

    1 trial

  16. AK104

    Akeso

    Advanced Malignant Tumors

    phase 2 small molecule active

    1 trial

  17. AK104

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Resectable Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  18. AK104, nab-paclitaxel, carboplatin

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  19. AK105 and anlotinib

    The First People's Hospital of Lianyungang

    Cervical Cancer

    phase 2 small molecule active

    1 trial

  20. AK112

    Summit Therapeutics

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  21. AK112, Cadonilimab, nab-paclitaxel, gemcitabine

    Akeso

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  22. AK117

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  23. AKB-6548

    Akebia Europe Limited

    Anemia

    phase 2 small molecule completed

    4 trials

  24. AKCEA-ANGPTL3-LRX

    IONIS PHARMACEUTICALS INC

    Homozygous Familial Hypercholesterolemia

    phase 2 small molecule terminated

    1 trial

  25. AKCEA-ANGPTL3-LRx

    IONIS PHARMACEUTICALS INC

    Familial Chylomicronemia Syndrome

    phase 2 small molecule completed

    1 trial

  26. AKCEA-ANGPTL3-LRx

    IONIS PHARMACEUTICALS INC

    Familial Partial Lipodystrophy

    phase 2 small molecule completed

    1 trial

  27. AL-335

    Janssen Cilag International NV

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  28. AL8326

    Lacuna Pharma Pty Ltd

    Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage., Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage.

    phase 2 small molecule active

    1 trial

  29. AL8326

    Lacuna Pharma Pty Ltd

    - Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage. - Non Small Cell Lung Cancer (NSCLC) patients who need ≥2nd line treatment with brain metastasis which is controlled with no active hemorrhage. - Renal Cell Carcinoma (RCC) patients who need ≥2nd line treatment., - Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage. - Non Small Cell Lung Cancer (NSCLC) patients who need ≥2nd line treatment with brain metastasis which is controlled with no active hemorrhage. - Renal Cell Carcinoma (RCC) patients who need ≥2nd line treatment.

    phase 2 small molecule active

    1 trial

  30. ALD518

    CSL Behring GmbH

    Oral Mucositis

    phase 2 mab terminated

    1 trial

  31. ALDARA 5% cream, Keramod® gel

    Lacuna Pharma Pty Ltd

    Actinic keratosis

    phase 2 small molecule active

    1 trial

  32. ALDESLEUKIN , TIL cells

    Disc Medicine

    Ovarian carcinoma

    phase 2 small molecule active

    1 trial

  33. ALDESLEUKIN , Tumor Intiltrating Lymphocytes (TIL) – VHIO, FLUDARABINE , CYCLOPHOSPHAMIDE

    The George Institute

    Germ Cell Tumors refractory to salvage chemotherapy

    phase 2 small molecule active

    1 trial

  34. ALECTINIB

    Hoffmann-La Roche

    ALK fusion-positive extracranial solid or primary CNS tumors who have progressed following prior treatment or who have no satisfactory treatment available

    phase 2 small molecule active

    1 trial

  35. ALEXAN, 50 MG/ML, ROZTWÓR DO INFUZJI, Liposomal Annamycin

    Moleculin Biotech

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  36. ALG-000184

    Aligos Therapeutics

    Chronic Hepatitis B Infection

    phase 2 small molecule active

    1 trial

  37. ALG-000184, ALG-000184 Placebo, Tenofovir Disoproxil Placebo, Tenofovirdisoproxil Amarox 245 mg Filmtabletten

    Aligos Therapeutics

    Chronic Hepatitis B Virus Infection

    phase 2 small molecule active

    1 trial

  38. ALG-055009

    Aligos Therapeutics

    NASH

    phase 2 small molecule completed

    1 trial

  39. ALG.APV-527

    Aptevo Therapeutics

    Solid Tumor

    phase 2 small molecule active

    1 trial

  40. ALIMTA 500 mg powder for concentrate for solution for infusion, ALIMTA 100 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PDC*lung01, PDC*lung01

    Lacuna Pharma Pty Ltd

    Non-small-cell lung cancer

    phase 2 small molecule active

    1 trial

  41. ALKS 2680, ALKS 2680, Placebo to match ALKS 2680, ALKS 2680

    Alkermes Pharma Ireland

    Idiopathic Hypersomnia (IH)

    phase 2 small molecule active

    1 trial

  42. ALLO-501A

    Allogene Therapeutics

    Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma

    phase 2 gene therapy active

    1 trial

  43. ALLO-605

    Allogene Therapeutics

    Relapsed/Refractory Multiple Myeloma

    phase 2 gene therapy terminated

    1 trial

  44. ALLO-647

    Allogene Therapeutics

    Relapsed/Refractory Large B Cell Lymphoma

    phase 2 mab terminated

    1 trial

  45. ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS

    Lxo Ireland Designated Activity Company

    Sars-CoV2

    phase 2 small molecule completed

    1 trial

  46. ALN-2232

    Alnylam Netherlands B.V.

    Obesity

    phase 2 small molecule active

    1 trial

  47. ALN-4324

    Alnylam Netherlands B.V.

    Obese or Overweight Healthy Volunteers

    phase 2 small molecule active

    1 trial

  48. ALN-4324

    Alnylam Netherlands B.V.

    Type 2 Diabetes Mellitus (T2DM)

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.